As on Wednesday, Esperion Therapeutics Inc. (NASDAQ: ESPR) started slowly as it slid -0.47% to $2.12, before settling in for the price of $2.13 at the close. Taking a more long-term approach, ESPR posted a 52-week range of $0.71-$3.40.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 7.64%. Meanwhile, its Annual Earning per share during the time was 23.09%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 88.01%. This publicly-traded company’s shares outstanding now amounts to $196.22 million, simultaneously with a float of $194.16 million. The organization now has a market capitalization sitting at $415.99 million. At the time of writing, stock’s 50-day Moving Average stood at $1.83, while the 200-day Moving Average is $2.25.
Esperion Therapeutics Inc. (ESPR) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Drug Manufacturers – Specialty & Generic industry. Esperion Therapeutics Inc.’s current insider ownership accounts for 1.05%, in contrast to 72.27% institutional ownership. According to the most recent insider trade that took place on Sep 17 ’24, this organization’s President and CEO sold 14,550 shares at the rate of 1.80, making the entire transaction reach 26,132 in total value, affecting insider ownership by 752,266. Preceding that transaction, on Sep 17 ’24, Company’s Chief Commercial Officer sold 2,608 for 1.78, making the whole transaction’s value amount to 4,650. This particular insider is now the holder of 162,659 in total.
Esperion Therapeutics Inc. (ESPR) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.05 per share during the current fiscal year.
Esperion Therapeutics Inc.’s EPS increase for this current 12-month fiscal period is 88.01% and is forecasted to reach 0.17 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 16.90% through the next 5 years, which can be compared against the 23.09% growth it accomplished over the previous five years trading on the market.
Esperion Therapeutics Inc. (NASDAQ: ESPR) Trading Performance Indicators
Let’s observe the current performance indicators for Esperion Therapeutics Inc. (ESPR). It’s Quick Ratio in the last reported quarter now stands at 1.49. The Stock has managed to achieve an average true range (ATR) of 0.14. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 1.50.
In the same vein, ESPR’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.88, a figure that is expected to reach -0.17 in the next quarter, and analysts are predicting that it will be 0.17 at the market close of one year from today.
Technical Analysis of Esperion Therapeutics Inc. (ESPR)
Through scrutinizing the latest numbers posted by the [Esperion Therapeutics Inc., ESPR], it can be observed that its last 5-days Average volume of 3.03 million was lower the volume of 6.35 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 82.00% While, its Average True Range was 0.14.
Raw Stochastic average of Esperion Therapeutics Inc. (ESPR) in the period of the previous 100 days is set at 35.06%, which indicates a major fall in contrast to 85.71% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 85.31% that was higher than 73.48% volatility it exhibited in the past 100-days period.
